<DOC>
	<DOCNO>NCT01908010</DOCNO>
	<brief_summary>This study investigate safety , tolerability pharmacokinetics ABT-354 20 male female subject , 55 90 year age mild moderate Alzheimer 's disease stable dose acetylcholinesterase inhibitor .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics ABT-354 Subjects With Mild-to-Moderate Alzheimer 's Disease Stable Doses Acetylcholinesterase Inhibitors</brief_title>
	<detailed_description>This double-blind , placebo-controlled , randomize , multiple-dose , multicenter study . Up 20 male female subject mild moderate Alzheimer 's disease ( AD ) take stable dos acetylcholinesterase inhibitor enrol study . Within 28 day prior study drug administration , subject screen base National Institute Neurological Communicative Disorders Stroke/Alzheimer 's Disease Related Disorders Association ( NINCDS/ADRDA ) criteria probable AD , Mini-Mental State Examination ( MMSE ) Modified Hachinski Ischemic Scale ( MHIS ) score , medical history , physical examination , neurological examination , vital sign , ECG , laboratory test response Columbia-Suicide Severity Rating Scale ( C-SSRS ) . The study perform two group 10 subject . In group 10 subject , 7 subject randomly assign receive ABT-354 3 subject receive match placebo .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>Meets National Institute Neurological Communicative Disorders Stroke/Alzheimer 's Disease Related Disorders Association criterion probable Alzheimer 's Disease Has MiniMental State Examination total score 16 26 , inclusive , Screening Has Modified Hachinski Ischemia Scale score â‰¤ 4 Screening On stable dose donepezil , galantamine rivastigmine least 30 day prior study drug administration Has computerize tomography magnetic resonance imaging scan , interpreted radiologist neurologist , within 36 month prior randomization Receipt depot drug injection within 30 day prior study drug administration Receipt investigational product within time period equal 10 halflives , know , within 6 week prior study drug administration History significant neurological disease Alzheimer 's Disease History significant sensitivity allergy multiple drug base medical record and/or opinion investigator Significant current suicidal ideation within 1 month prior study drug administration evidence answer `` yes '' question 4 5 suicidal ideation portion ColumbiaSuicide Severity Rating Scale complete Screening history suicide attempt</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Alzheimer 's disease</keyword>
</DOC>